MONURAL (monurol) ® 3 g packet №1

Description for MONURAL ® 3 g packet

Pharmacological properties:
Pharmacodynamics. Monural has a broad spectrum of antibacterial action. It is effective with respect to the most commonly available strains of urinary tract infections: E. coli, Klebsiella spp., Enterobacter spp., Pseudomonas spp., Staphylococcus spp., even if they are resistant to other antibiotics. The drug also acts on penitsillinazoobrazuyuschie strains. Monural has antiadgezivnoe effect on the bacteria having the property of adhesion (sticking) to the epithelium of the urinary tract.
Pharmacokinetics. Monural readily absorbed in the gastrointestinal tract, maximum plasma concentration observed after 2 h and is 30-35 mg / ml, elimination half-life of blood plasma - 2 hours Monural not metabolized in the body, it is excreted by glomerular filtration in the biologically active form. Monural accumulates mainly in the kidneys at a concentration of 2500 - 3500 pg / ml, and the minimum inhibitory concentration for E. monurala coli is 128 ug / ml. Enterohepatic circulation Monurala can maintain a therapeutic level of drug over 48 hours - a time sufficient to sterilize the urine and recovery.

INDICATIONS: acute bacterial cystitis, acute attacks of recurrent bacterial cystitis, acute bacterial uretrovezikalny syndrome, bacterial non-specific urethritis, asymptomatic bacteriuria is massive (during pregnancy), post-operative urinary tract infection, prevention of urinary tract infections during surgery and transurethral diagnostic studies.

APPLICATION: Monural administered orally (2 hours before or after meals), preferably before bedtime. The contents of the package was dissolved in 1 / 3 cup water. The dosage regimen is determined individually. Usually a single dose for adults in the acute phase of illness is 3 grams (1 packet) one-off.
In chronic disease course, as well as elderly patients the drug is used twice on 3 g with an interval of 24 h.
In order to prevent urinary tract infections in the surgical procedure, transurethral diagnostic tests take the contents of a package of 3 h before the intervention and the second package at 24 h after the first.

Contraindications: Hypersensitivity to the drug, severe renal impairment (creatinine clearance ≤ 10 mL / min), children under the age of 12 years.

SIDE EFFECTS: gastrointestinal disorders (diarrhea, heartburn, nausea), skin rash.

SPECIAL INSTRUCTIONS: simultaneous ingestion slows the absorption of Monurala.
Patients with diabetes need to take into account that a package Monurala contained 2.213 g of sucrose.
Possible transient increase in liver transaminases.
During pregnancy and lactation. Use during pregnancy and breast-feeding is possible only for health reasons or if the effect of therapy to the mother justifies the potential risk to the fetus. Adequate and strictly controlled studies on the use during pregnancy has not been conducted. Therefore, we must take into account the ability of fosfomycin to penetrate through the placenta. For a period of treatment of the mother should stop breastfeeding.

INTERACTION: simultaneous reception with metoclopramide reduces the absorption of Monurala, which leads to a decrease Monurala in serum and urine.

OVERDOSE: risk of overdose is minimal. In case of overdose recommended to consume plenty of fluids (to increase urine output). Symptomatic therapy.

STORAGE: Do not require special storage conditions.